Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings outcomes as we speak.
Reported gross sales elevated 5.3% year-over-year to $22.5 billion. Operational gross sales development was 6.7%.
Web earnings decreased 17% to $3.4 billion, or $1.41 per share, in comparison with final yr. Adjusted EPS decreased 10.9% to $2.04.
Income surpassed projections whereas earnings got here according to estimates.
For full-year 2025, the corporate expects reported gross sales of $89.2-90.0 billion and adjusted EPS of $10.50-10.70.
The inventory stayed pink in premarket hours on Wednesday.
Prior efficiency
